The store will not work correctly when cookies are disabled.
2-((4-(1-aminoethyl)phenyl)amino)-6-fluorobenzo[d]thiazole-4-carboxamide
ID: ALA5189956
PubChem CID: 168280822
Max Phase: Preclinical
Molecular Formula: C16H15FN4OS
Molecular Weight: 330.39
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: CC(N)c1ccc(Nc2nc3c(C(N)=O)cc(F)cc3s2)cc1
Standard InChI: InChI=1S/C16H15FN4OS/c1-8(18)9-2-4-11(5-3-9)20-16-21-14-12(15(19)22)6-10(17)7-13(14)23-16/h2-8H,18H2,1H3,(H2,19,22)(H,20,21)
Standard InChI Key: RGHKHQZIJWLVAA-UHFFFAOYSA-N
Molfile:
RDKit 2D
23 25 0 0 0 0 0 0 0 0999 V2000
-2.6410 -0.9587 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9265 -0.5464 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2145 -0.9583 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2145 -1.7835 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.9246 -2.1951 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6410 -1.7872 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.4298 -2.0384 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
-0.4298 -0.7033 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.0551 -1.3710 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8802 -1.3710 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.2928 -0.6563 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.8805 0.0584 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2925 0.7705 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1179 0.7705 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5298 0.0602 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1216 -0.6563 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5305 1.4851 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1179 2.1998 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.3557 1.4851 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.3557 -2.1998 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-1.9265 0.2787 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.6410 0.6913 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-1.2118 0.6913 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 2 0
4 7 1 0
3 8 1 0
8 9 2 0
9 7 1 0
9 10 1 0
10 11 1 0
12 11 2 0
13 12 1 0
14 13 2 0
15 14 1 0
16 15 2 0
11 16 1 0
14 17 1 0
17 18 1 0
17 19 1 0
6 20 1 0
2 21 1 0
21 22 2 0
21 23 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 330.39 | Molecular Weight (Monoisotopic): 330.0951 | AlogP: 3.30 | #Rotatable Bonds: 4 |
Polar Surface Area: 94.03 | Molecular Species: BASE | HBA: 5 | HBD: 3 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 12.68 | CX Basic pKa: 9.59 | CX LogP: 2.77 | CX LogD: 0.64 |
Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.68 | Np Likeness Score: -1.93 |
References
1. Nizi MG, Maksimainen MM, Lehtiö L, Tabarrini O.. (2022) Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules., 65 (11.0): [PMID:35608571] [10.1021/acs.jmedchem.2c00281] |